Prices delayed by at least 15 minutes | Print
Legal & General Ucits Etf Public Limited Company L&G PHARMA BREAKTHROUGH GO UCITS ETF
Open
$15.10
Previous close
$15.136
Trade high
$15.40
Income frequency
-
Year low
$12.376
Year high
$16.19
Replication method
Physical Full
Volume
747
Type
ETF
UCITS
Yes
Dividend yield
–
Ongoing charge
0.49
ISIN
IE00BF0H7608
Share price
Asset allocation
Top 10 holdings
| Holdings 13/11/2026 | % of assets |
|---|---|
| Xeris Biopharma Holdings Inc | 4.96 |
| Genmab AS | 3.84 |
| Xencor Inc | 3.54 |
| United Therapeutics Corp | 3.08 |
| BeOne Medicines Ltd ADR | 2.95 |
| Biogen Inc | 2.92 |
| AstraZeneca PLC | 2.89 |
| Basilea Pharmaceutica Ltd Registered Shares | 2.79 |
| Royalty Pharma PLC Class A | 2.75 |
| Ligand Pharmaceuticals Inc | 2.75 |
Investment objective
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.